^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Mantle Cell Lymphoma: Less aggressive therapy…Preferred…Lenalidomide + rituximab
